EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The microRNA Expression Signature of Lung Adenocarcinoma Harboring EGFR Mutations: Identification of Therapeutic Targets for EGFR-TKI Combination Therapy

Takuya Tokunaga iD, Yuya Tomioka iD, Aya Harada Takeda iD, Yuka Ishihara, Ayako Nagata iD, Mayuko Kato iD, Takayuki Suetsugu, Keiko Mizuno iD, Masaya Aoki iD, Kazuhiro Ueda iD, Naohiko Seki iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27146412 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Takuya Tokunaga und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan. Hauptthemen laut MEDLINE: MicroRNAs, Mutation, Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Approximately half of Japanese patients with lung adenocarcinoma (LUAD) have epi-dermal growth factor receptor (EGFR) gene mutations. Therefore, EGFR is the most critical therapeutic target in treating LUAD. This study’s purpose is to explore novel therapeutic targets for LUAD and further improve EGFR inhibitor combination therapy. We created microRNA (miRNA) expression signatures from clinical specimens of LUAD patients harboring EGFR gene mutations using RNA sequencing. Based on the miRNA signature, we focused on miR-206, which had the most downregulated expression. We searched for its target gene in LUAD cells by facilitating transfection of miR-206 into the EGFR mutant cell line PC9 and searching for genes with suppressed expression. A total of 821 genes were downregulated in PC9 cells. Through molecular classification of these genes, we revealed that 18 genes were closely related to the cell cycle. Among these genes, we focused on cyclin-dependent kinase 4 (CDK4) and investigated the synergistic effects of a CDK4/6 inhibitor (abemaciclib or palbociclib) and osimertinib, an EGFR inhibitor in LUAD cells. In vitro and three-dimensional culture analyses showed that combination therapy with a CDK4/6 inhibitor and an EGFR inhibitor synergistically suppressed proliferation of LUAD cells with EGFR mutations. Our miRNA-based analysis is an excellent strategy for identifying therapeutic targets for LUAD. Continued analysis will reveal target molecules that enhance the therapeutic effects of EGFR inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsMutationAdenocarcinoma of LungLung NeoplasmsProtein Kinase InhibitorsHumansErbB ReceptorsCell Line, TumorGene Expression Regulation, NeoplasticAniline CompoundsPyrimidinesAcrylamidesIndolesPyridinesCyclin-Dependent Kinase 4PiperazinesCyclin-Dependent Kinase 6Benzimidazoles

Stichwörter der Autor:innen

CDK4CDK4/6 inhibitorEGFR mutationlung adenocarcinomamiR-206microRNAosimertinib

Substanzen

MicroRNAsErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanAniline CompoundsPyrimidinesAcrylamidesIndolesosimertinibMIR206, human

Autor:innen und Institutionen

  • Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
  • Department of Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
  • Department of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.

ORCID-Profile: Takuya Tokunaga, Yuya Tomioka, Aya Harada Takeda, Ayako Nagata, Mayuko Kato, Keiko Mizuno, Masaya Aoki, Kazuhiro Ueda, Naohiko Seki

Förderung

  • Japan Society for the Promotion of Science
  • KAKENHI

Zitieren

APA

Tokunaga, T., Tomioka, Y., Takeda, A. H., Ishihara, Y., Nagata, A., Kato, M., Suetsugu, T., Mizuno, K., Aoki, M., Ueda, K., & Seki, N. (2026). The microRNA Expression Signature of Lung Adenocarcinoma Harboring EGFR Mutations: Identification of Therapeutic Targets for EGFR-TKI Combination Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27146412

Vancouver

Tokunaga T, Tomioka Y, Takeda AH, Ishihara Y, Nagata A, Kato M, et al. The microRNA Expression Signature of Lung Adenocarcinoma Harboring EGFR Mutations: Identification of Therapeutic Targets for EGFR-TKI Combination Therapy. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27146412

BibTeX
@article{Tokunaga2026,
  author = {Tokunaga, Takuya and Tomioka, Yuya and Takeda, Aya Harada and Ishihara, Yuka and Nagata, Ayako and Kato, Mayuko and Suetsugu, Takayuki and Mizuno, Keiko and Aoki, Masaya and Ueda, Kazuhiro and Seki, Naohiko},
  title = {The microRNA Expression Signature of Lung Adenocarcinoma Harboring EGFR Mutations: Identification of Therapeutic Targets for EGFR-TKI Combination Therapy},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27146412}
}
Kostenlos starten →